Niagen Bioscience (NAGE) announced that it has acquired a portfolio of existing patents covering nicotinamide riboside and its salt forms from Queen’s University Belfast. The acquired portfolio comprises the core body of patents underpinning the production, composition, and commercial use of NR, encompassing foundational composition-of-matter patents covering crystal morphologies, methods of making NR and other NAD+ precursors, and global patent rights spanning multiple jurisdictions. Prior to this transaction, Niagen Bioscience previously held exclusive rights to these patents through long-standing licensing and joint ownership arrangements with QUB. With this acquisition, Niagen Bioscience now becomes the sole owner of this IP portfolio.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience management to meet with Roth Capital
- Niagen Bioscience announces results of Niagen supplementation in long COVID
- Niagen Bioscience announces $10M share repurchase program
- Niagen Bioscience Announces $10 Million Share Buyback
- ChromaDex Reports Record Growth Amid Strategic Expansions